Franco Maggiolo

Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Nonnucleoside Analogues or Protease Inhibitors

Franco Maggiolo, Laura Ravasio, D Ripamonti et al. · Clinical Infectious Diseases · 2004 · 222 citations · Full text

One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects

Franco Maggiolo · Patient Preference and Adherence · 2010 · 181 citations · Full text

Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients

Franco Maggiolo, Monica Airoldi, Daniël Kleinloog et al. · HIV Clinical Trials · 2007 · 162 citations · Full text

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng et al. · Clinical Infectious Diseases · 2022 · 152 citations · Full text

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens et al. · The Lancet HIV · 2019 · 141 citations

Week 96, Antiviral Drug Development, Antiviral Therapy +8